B of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $7

Benzinga · 11/18/2025 17:59
B of A Securities analyst Jason Zemansky maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and lowers the price target from $8 to $7.